Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copper gluconate/disulfiram - Cantex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Copper gluconate/disulfiram - Cantex Pharmaceuticals

Alternative Names: CX 02; Dicopp; Disulfiram/copper gluconate - Cantex Pharmaceuticals; DSF-Cu

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cantex Pharmaceuticals
  • Class Antineoplastics; Heavy metals; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase inhibitors; Cell death stimulants; Proteasome inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Pancreatic cancer; Prostate cancer
  • No development reported Brain metastases; Multiple myeloma; Myelodysplastic syndromes; Triple negative breast cancer

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (PO)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA
  • 06 Feb 2022 Cantex Pharmaceuticals terminates phase I trial in Multiple myeloma (Second-line therapy or greater) in USA (unspecified route) (NCT04521335)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top